Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Trials

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Apr 06, 2024 12:21pm

136 Views

Post# 35974838

RE:RE:RE:RE:RE:Trials

Oncolytics has removed all references to Phase 3 trials from its investor presentation.

Think about that for a minute.

Two days ago they were a company that was due to begin TWO PHASE 3 TRIALS (BC and Panc).

Now they don't even want to use the phrase "Phase 3 trial"

I suggest "investors" spend some time asking chatgpt about the difference between registration enabling trials vs phase 3 trials.

Phase 3 is the GOLD STANDARD and everyone knows what it means.

Registration Enabling is fuzzy and could mean a hundred different things.

Once again, ONC leaves us wondering. MC is a master at this scheme.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023